Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma

7 maja 2026 zaktualizowane przez: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

A Randomized, Open-Label, Multicenter Phase III Clinical Trial to Evaluate the Efficacy and Safety of TQB2934 Injection Versus Investigator-Selected Regimens in Patients With Relapsed/Refractory Multiple Myeloma

This study is a randomized, open-label, multicenter Phase III clinical trial involving patients with relapsed/refractory multiple myeloma. The estimated total sample size is 260 cases, who will be randomly assigned in a 1:1 ratio to the test group and the control group. The primary objective of the study is to demonstrate the efficacy of TQB2934 for injection compared to the investigator-selected regimen in subjects with relapsed or refractory multiple myeloma (RRMM) by evaluating progression-free survival (PFS).

Przegląd badań

Status

Jeszcze nie rekrutacja

Warunki

Interwencja / Leczenie

Typ studiów

Interwencyjne

Zapisy (Szacowany)

260

Faza

  • Faza 3

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Kontakt w sprawie studiów

Lokalizacje studiów

  • Chiny
    • Anhui
      • Bengbu, Anhui, Chiny, 233004
        • The First Affiliated Hospital of Bengbu Medical University
        • Kontakt:
          • Jiajia Li, Doctor
          • Numer telefonu: 13955207283
          • E-mail: 4119469@qq.com
      • Hefei, Anhui, Chiny, 230022
        • The First Affiliated Hospital of Anhui Medical University
        • Kontakt:
    • Beijing Municipality
      • Beijing, Beijing Municipality, Chiny, 100020
        • Beijing Chao-Yang Hospital,Capital Medical University
      • Beijing, Beijing Municipality, Chiny, 100020
        • Beijing Jishuitan Hospital,Capital Medical University
        • Kontakt:
    • Chongqing Municipality
      • Chongqing, Chongqing Municipality, Chiny, 400010
        • The First Affiliated Hospital of Chongqing Medical University
        • Kontakt:
      • Chongqing, Chongqing Municipality, Chiny, 400038
        • The Southwest Hospital of Amu
        • Kontakt:
    • Gansu
      • Lanzhou, Gansu, Chiny, 730030
        • Lanzhou University Second Hospital
        • Kontakt:
      • Lanzhou, Gansu, Chiny, 730000
        • Gansu Provincial Maternal and Child Health Hospital (Gansu Provincial Central Hospital)
        • Kontakt:
    • Guangdong
      • Guangzhou, Guangdong, Chiny, 510280
        • Zhujiang Hospital of Southern Medical University
        • Kontakt:
      • Guangzhou, Guangdong, Chiny, 510000
        • Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
        • Kontakt:
      • Guangzhou, Guangdong, Chiny, 510062
        • Sun Yat-sen University Cancer Center
        • Kontakt:
      • Zhanjiang, Guangdong, Chiny, 524023
        • Affiliated Hospital Of Guangdong Medical University
        • Kontakt:
          • Honghua He, Master
          • Numer telefonu: 13828229695
          • E-mail: 192880@qq.com
    • Guangxi
      • Nanning, Guangxi, Chiny, 530000
        • The First Affiliated Hospital of Guangxi Medical University
        • Kontakt:
    • Guizhou
      • Guiyang, Guizhou, Chiny, 550001
        • The Affiliated Hospital of Guizhou Medical University
        • Kontakt:
    • Hebei
      • Cangzhou, Hebei, Chiny, 061000
        • Cangzhou People's Hospital
        • Kontakt:
      • Chengde, Hebei, Chiny, 067000
        • Affiliated Hospital of Chengde Medical University
        • Kontakt:
      • Shijiazhuang, Hebei, Chiny, 050000
        • The Second Hospital of Hebeimedical University
        • Kontakt:
    • Heilongjiang
      • Harbin, Heilongjiang, Chiny, 150086
        • The Second Affiliated Hospital of Harbin Medical University
        • Kontakt:
    • Henan
      • Luoyang, Henan, Chiny, 471000
        • Luoyang Central Hospital
        • Kontakt:
      • Zhengzhou, Henan, Chiny, 450000
        • Henan Cancer Hospital
        • Kontakt:
      • Zhengzhou, Henan, Chiny, 450000
        • Henan Provincial People's Hospital
        • Kontakt:
      • Zhengzhou, Henan, Chiny, 451191
        • The first affiliated hospital of Zhengzhou university
        • Kontakt:
    • Hunan
      • Changsha, Hunan, Chiny, 410013
        • The Third Xiangya Hospital of Central South University
        • Kontakt:
      • Zhuzhou, Hunan, Chiny, 412007
        • ZhuZhou Central Hospital
        • Kontakt:
    • Jiangsu
      • Nanjing, Jiangsu, Chiny, 210029
        • Jiangsu Province Hospital
        • Kontakt:
      • Nanjing, Jiangsu, Chiny, 210009
        • Zhongda Hospital Southeast University
        • Kontakt:
      • Xuzhou, Jiangsu, Chiny, 221004
        • The Affiliated Hospital of Xuzhou Medical University
        • Kontakt:
    • Jiangxi
      • Nanchang, Jiangxi, Chiny, 330006
        • The Second Affiliated Hospital of Nanchang University
        • Kontakt:
      • Nanchang, Jiangxi, Chiny, 330038
        • Jiangxi Provincial People's Hospital
        • Kontakt:
    • Liaoning
      • Shenyang, Liaoning, Chiny, 110000
        • Shengjing Hospital Of China Medical University
        • Kontakt:
    • Shaanxi
      • Xi'an, Shaanxi, Chiny, 710004
        • The Second Affiliated Hospital of Xi'an Jiaotong University
        • Kontakt:
      • Xi'an, Shaanxi, Chiny, 710048
        • The First Affiliated Hospital of Xi'an Jiao Tong University
        • Kontakt:
    • Shandong
      • Binzhou, Shandong, Chiny, 256600
        • Binzhou Medical University Hospital
        • Kontakt:
      • Jinan, Shandong, Chiny, 250117
        • Cancer Hospital of Shandong First Medical University (Shandong Cancer Institute,Shandong Cancer Hospital)
        • Kontakt:
      • Jinan, Shandong, Chiny, 250021
        • Shandong Provincial Hospital Affiliated to Shandong First Medical University（Shandong Provincial Hospital）
        • Kontakt:
      • Jining, Shandong, Chiny, 272111
        • Jining No.1 People's Hospital
        • Kontakt:
      • Qingdao, Shandong, Chiny, 266011
        • Qingdao Municipal Hospital
        • Kontakt:
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Chiny, 200032
      • Shanghai, Shanghai Municipality, Chiny, 200233
    • Shanxi
      • Changzhi, Shanxi, Chiny, 46000
        • Heping Hospital Affiliated to Changzhi Medical College
        • Kontakt:
      • Taiyuan, Shanxi, Chiny, 30000
        • Shanxi Provincial Cancer hospital
        • Kontakt:
    • Sichuan
      • Chengdu, Sichuan, Chiny, 610072
        • Sichuan Academy of Medical Sciences ＆ Sichuan Provincial People's Hospital
        • Kontakt:
      • Luzhou, Sichuan, Chiny, 646000
        • The affiliated hospital of Southwest Medical University
        • Kontakt:
    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, Chiny, 300121
        • Tianjin Union Medical Center
    • Xinjiang
      • Ürümqi, Xinjiang, Chiny, 830000
        • People's Hospital of Xinjiang Uygur Autonomous Region
        • Kontakt:
    • Yunnan
      • Kunming, Yunnan, Chiny, 650000
        • The First Affiliated Hospital of Kunming Medical University
        • Kontakt:
    • Zhejiang
      • Hangzhou, Zhejiang, Chiny, 310000
        • The First Affiliated Hospital, College of Medicine, Zhejiang University
      • Ningbo, Zhejiang, Chiny, 315000
        • The First Affiliated Hospital of Ningbo Universty
        • Kontakt:
          • Kaihong Xu, Doctor
          • Numer telefonu: 13605887040
          • E-mail: xukaho@163.com
      • Ningbo, Zhejiang, Chiny, 315016
        • Ningbo No.2 Hospitai
        • Kontakt:

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

  • Dorosły
  • Starszy dorosły

Akceptuje zdrowych ochotników

Nie

Opis

Inclusion Criteria:

  • Voluntarily join this study, sign the Informed Consent Form (ICF), and demonstrate good compliance.
  • Aged 18 to 75 years old (as of the date of signing the ICF); gender not limited; Eastern Cooperative Oncology Group Performance Status (ECOG) of 0-2.
  • Expected survival greater than 3 months.
  • Patients with relapsed or refractory multiple myeloma.
  • During or after the most recent treatment, there is evidence of disease progression or failure to achieve remission after the last line of treatment。
  • Measurable disease at screening.
  • Adequate organ function as indicated by laboratory tests meeting the criteria.
  • Women of childbearing potential must agree to use effective contraception during the study and for 12 months after the last dose of study treatment, and agree not to donate eggs for reproduction during this period. Must not be breastfeeding and must have a negative serum or urine pregnancy test within 7 days prior to enrollment. Men who have not had a vasectomy and their female partners of childbearing potential should also agree to use effective contraception during the study and for 12 months after the last dose of study treatment, and agree not to donate sperm during this period.

Exclusion Criteria:

  • History of other malignancies within 5 years prior to informed consent or concurrent presence of other malignancies. The following exceptions are allowed: other malignancies cured by surgery alone with a disease-free survival (DFS) ≥5 years; cured carcinoma in situ of the cervix, non-melanoma skin cancer, and superficial bladder tumors [Ta (non-invasive tumor), Tis (carcinoma in situ), and T1 (tumor invading the basement membrane)].
  • Diagnosis of plasma cell leukemia (defined as circulating plasma cells ≥5% in peripheral blood according to standard classification), Waldenström macroglobulinemia, primary light-chain (AL) amyloidosis, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein [M protein], and skin changes), or solitary plasmacytoma.

  • History of prior anticancer treatment, including but not limited to:

    1. Receipt of chimeric antigen receptor T-cell (CAR-T), Chimeric Antigen Receptor T-Cell Immunotherapy(CAR-T), Chimeric Antigen Receptor Natural Killer Cells (CAR-NK), or other cellular therapies within 3 months prior to randomization;
    2. Receipt of autologous stem cell transplantation within 3 months prior to randomization;
    3. Receipt of allogeneic stem cell transplantation within 6 months prior to randomization; subjects must have discontinued all immunosuppressive therapy for ≥6 weeks and have no signs or symptoms of graft-versus-host disease (GVHD);
    4. Receipt of molecular targeted therapy, investigational drugs, or invasive investigational medical devices within 3 weeks or 5 drug half-lives (whichever is shorter) prior to randomization;
    5. Receipt of monoclonal antibodies, bispecific antibodies, chemotherapy, etc., within 3 weeks prior to randomization;
    6. Receipt of proteasome inhibitors (PI), immunomodulatory drugs (IMiDs), localized radiotherapy, palliative radiotherapy, or Chinese patent medicines with antitumor indications approved by the National Medical Products Administration (NMPA) within 2 weeks prior to randomization.
  • Previously refractory to control group drugs, or with contraindications, life-threatening allergic reactions, or intolerance to previous treatments.
  • Receipt of systemic corticosteroids at a cumulative dose ≥140 mg prednisone (or equivalent) within 2 weeks prior to randomization. Topical, ophthalmic, intra-articular, intranasal, and inhaled corticosteroids are excluded from the cumulative dose calculation (see Appendix for dose conversion).
  • Toxicities from prior antitumor therapy have not recovered to baseline or ≤ Grade 1, except for Grade 2 alopecia, non-clinically significant and asymptomatic laboratory abnormalities, and hypothyroidism stabilized by hormone replacement therapy, as judged by the investigator to pose no safety risk.
  • History of Grade ≥3 cytokine release syndrome (CRS) associated with any T-cell redirecting therapy (e.g., CD3-redirecting therapies or CAR-T cell therapy).
  • Presence of conditions affecting intravenous infusion or blood collection, dysphagia, chronic diarrhea, intestinal obstruction, or other active gastrointestinal dysfunction that may interfere with drug administration or absorption.
  • Known central nervous system (CNS) involvement of multiple myeloma (MM), or clinical signs/symptoms suggestive of leptomeningeal involvement. If either is suspected, both brain MRI and lumbar puncture cytology must be negative.
  • Major surgery, significant traumatic injury, or planned major surgery during the study treatment period within 4 weeks prior to randomization, or presence of non-healed wounds or fractures (major surgery defined as Grade ≥3 according to the 2022 national surgical classification catalogue).
  • Any severe (≥ CTCAE Grade 3) bleeding or hemorrhagic event within 6 months prior to randomization.
  • Arterial or venous thrombotic events within 6 months prior to randomization, including cerebrovascular events (including transient ischemic attack), deep vein thrombosis, pulmonary embolism, or any other serious thromboembolism (implantable venous port- or catheter-related thrombosis and superficial thrombosis are not considered "serious").
  • Active hepatitis or decompensated cirrhosis (Child-Pugh Class B or C)
  • Significant cardiovascular disease.
  • Neurological or psychiatric disorders.

  • Pulmonary diseases, including any of the following:

    1. Current or prior non-infectious pneumonitis requiring corticosteroid treatment (including but not limited to acute respiratory distress syndrome, acute hypersensitivity pneumonitis, drug-related pneumonitis, bronchospasm, acute interstitial pneumonitis, idiopathic pulmonary fibrosis, etc.);
    2. Known or suspected chronic obstructive pulmonary disease (COPD) with forced expiratory volume in 1 second (FEV1) <60% of predicted.
  • Active or uncontrolled infections (≥ CTCAE Grade 2), including bacterial, fungal, or viral infections, such as active pneumonia/pulmonary infection, syphilis, tuberculosis, or Corona Virus Disease 2019 (COVID-19). Subjects with positive Cytomegalovirus (CMV) DNA or Epstein-Barr virus (EBV) plasma DNA during screening are not eligible.
  • Current or prior autoimmune diseases requiring systemic treatment. Subjects with hypothyroidism on stable replacement therapy, well-controlled type 1 diabetes, or skin diseases not requiring systemic therapy (e.g., vitiligo, psoriasis) are eligible.
  • History of immunodeficiency, including HIV positivity or other acquired or congenital immunodeficiency disorders.
  • Known or suspected history of hemophagocytic lymphohistiocytosis (HLH).
  • Known history of hypersensitivity to humanized monoclonal antibodies, or known allergy, hypersensitivity, or intolerance to any component of the investigational product.
  • Any other severe, acute, or chronic medical or psychiatric condition or laboratory abnormality that, in the investigator's opinion, may increase the risk associated with study participation or interfere with interpretation of study results.
  • Investigator considers that the subject is likely to have poor compliance with study participation.

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Brak (otwarta etykieta)

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: TQB2934 injection
TQB2934 injection, 28 days as a treatment cycle.
Lek: TQB2934 injection
TQB2934 injection is a bispecific antibody targeting B-cell maturation antigen (BCMA) and Cluster of Differentiation 3 (CD3).
Aktywny komparator: Selinexor and Dexamethasone or Pomalidomide Dexamethasone
Selinexor and Dexamethasone, 28 days as a treatment cycle or Pomalidomide Dexamethasone, 28 days as a treatment cycle
Lek: Pomalidomide Capsule
Pomalidomide capsules are an immunomodulatory(IMiD).
Lek: Selinexor tablets
Selinexor is a selective nuclear export protein inhibitor.
Lek: Dexamethasone tablets
Dexamethasone tablets are a type of adrenocortical hormone drug.

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Progression-free survival (PFS)
Ramy czasowe: Baseline up to 5 years
The time from randomization to disease progression or death from any cause, whichever occurs first.
Baseline up to 5 years

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Investigator-assessed PFS
Ramy czasowe: Baseline up to 5 years
The time from randomization to disease progression or death from any cause, whichever comes first.
Baseline up to 5 years
PFS rates at 6, 12 and 18 months
Ramy czasowe: From baseline to 18 months
The proportion of patients who remain free from disease progression or death at 6, 12 and 18 months after randomization.
From baseline to 18 months
Overall response rate (ORR)
Ramy czasowe: Baseline up to 5 years
The proportion of patients with a complete response (CR) or partial response (PR) after treatment.
Baseline up to 5 years
Very Good Partial Response (VGPR)
Ramy czasowe: Baseline up to 5 years
The best overall response is defined as the sum proportion of subjects achieving stringent complete response (sCR), complete response (CR), and very good partial response (VGPR). or very good partial response (VGPR).
Baseline up to 5 years
Complete Response (CR) Rate
Ramy czasowe: Baseline up to 5 years
The percentage of evaluable subjects who achieve complete response (CR).
Baseline up to 5 years
Duration of remission (DOR)
Ramy czasowe: Baseline up to 5 years
The time from the first onset of objective response to the first documentation of disease progression or death from any cause, whichever occurs first.
Baseline up to 5 years
Time to first remission (TTR)
Ramy czasowe: Baseline up to 5 years
The time from randomization to the first achievement of objective response.
Baseline up to 5 years
Negative rate of minimal residual disease (MRD)
Ramy czasowe: Baseline up to 5 years
The proportion of subjects achieving MRD negativity.
Baseline up to 5 years
Overall survival (OS)
Ramy czasowe: From randomization to death, the estimated evaluation period is up to 5 years
Time from randomization to death.
From randomization to death, the estimated evaluation period is up to 5 years
Adverse event rate
Ramy czasowe: From randomization to 2 months after the last dose
The occurrence of all adverse events (AEs), serious adverse events (SAEs) and treatment-related adverse events (TEAEs).
From randomization to 2 months after the last dose
Peak concentration (Cmax)
Ramy czasowe: Before Pre-dose, before dose of Cycle 1 Day 1, Cycle 2 Day 1, Cycle 6 Day 1, Cycle 12 Day 1, after dose of Cycle 2 Day 1, Cycle 6 Day 1，Last visit (up to 5 years), each cycle is 28 days.
Maximum plasma drug concentration.
Before Pre-dose, before dose of Cycle 1 Day 1, Cycle 2 Day 1, Cycle 6 Day 1, Cycle 12 Day 1, after dose of Cycle 2 Day 1, Cycle 6 Day 1，Last visit (up to 5 years), each cycle is 28 days.
Anti-drug antibody (ADA) positive rate
Ramy czasowe: Before Pre-dose, before dose of Cycle 1 Day 1, Cycle 2 Day 1, Cycle 6 Day 1, Cycle 12 Day 1, Last visit (up to 5 years) and 30 days after the last administration each, each cycle is 28 days.
The proportion of evaluable subjects with positive test results for anti-drug antibody (ADA).
Before Pre-dose, before dose of Cycle 1 Day 1, Cycle 2 Day 1, Cycle 6 Day 1, Cycle 12 Day 1, Last visit (up to 5 years) and 30 days after the last administration each, each cycle is 28 days.
Nab positive rate
Ramy czasowe: Before Pre-dose, before dose of Cycle 1 Day 1, Cycle 2 Day 1, Cycle 6 Day 1, Cycle 12 Day 1, Last visit (up to 5 years) and 30 days after the last administration each, each cycle is 28 days.
The percentage of evaluable subjects with positive neutralizing antibody (NAB) test results in all evaluable subjects.
Before Pre-dose, before dose of Cycle 1 Day 1, Cycle 2 Day 1, Cycle 6 Day 1, Cycle 12 Day 1, Last visit (up to 5 years) and 30 days after the last administration each, each cycle is 28 days.

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Szacowany)

1 czerwca 2026

Zakończenie podstawowe (Szacowany)

1 grudnia 2028

Ukończenie studiów (Szacowany)

1 grudnia 2030

Daty rejestracji na studia

Pierwszy przesłany

29 kwietnia 2026

Pierwszy przesłany, który spełnia kryteria kontroli jakości

29 kwietnia 2026

Pierwszy wysłany (Rzeczywisty)

6 maja 2026

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

8 maja 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

7 maja 2026

Ostatnia weryfikacja

1 lutego 2026

Więcej informacji

Terminy związane z tym badaniem

Dodatkowe istotne warunki MeSH

Inne numery identyfikacyjne badania

  • TQB2934-III-01

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Badania kliniczne na Szpiczak mnogi

Badania kliniczne na TQB2934 injection

Wyszukaj podobne próby

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

CROs by country

CROs in Mauritania

Warunki

Rzadkie choroby

Interwencje lekowe

Suplementy diety

Sponsor / Współpracownicy

Lokalizacje

Subskrybuj